Abbott’s growth
January 27, 2011
ABBOTT Laboratories and
Subsidiaries has reported double
digit growth in its fourth quarter,
clocking an EPS (earnings per
share) increase of 10.2%.
Worldwide sales for the group
also showed promise, with figures
jumping 13.4% to nearly US$10
billion, for the period ending 31
December 2010.
Abbott has said that growth in
the quarter was primarily driven by
pharmaceutical sales, which
increased 22%, including
contributions provided via its
acquisition of both Solvay and
Pirmal, as well as worldwide
vascular products sales, which
increased 13.7%.
“Despite a very challenging
environment, 2010 was another
productive year for Abbott,
resulting in strong financial
performance,” said Miles White,
chairman and chief executive
officer, Abbott.
“We also took decisive long-term
strategic actions to expand our
emerging markets presence and
late-stage pipeline to better
position Abbott for sustainable
long-term growth,” he added.
Meanwhile, Abbott has said that
it anticipates another year of doubledigit
ongoing EPS growth in 2011.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jan 11To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jan 11
